Understanding Intermediate and Posterior Uveitis
Intermediate uveitis is a form of intraocular inflammation that primarily affects the vitreous, the gel-like substance filling the center of the eye, and the pars plana, a narrow region located behind the iris. This condition is sometimes referred to as pars planitis, particularly when no underlying systemic disease can be identified. Intermediate uveitis can affect one or both eyes and tends to follow a chronic or relapsing course that requires ongoing attention.
Because the inflammation occurs in the middle portion of the eye rather than in the front chamber, intermediate uveitis often presents differently from the more common anterior uveitis. Patients may not experience the redness or acute eye pain typically associated with front-of-eye inflammation. Instead, the condition may develop gradually, making early detection through comprehensive eye examinations especially important.
Posterior uveitis involves inflammation at the back of the eye, affecting the choroid, the retina, or both structures simultaneously. When inflammation targets the choroid, the condition is called choroiditis. When it affects the retina, it is known as retinitis. When both layers are involved, the term chorioretinitis is used. These structures are essential for converting light into the neural signals that produce vision, so inflammation in this area can have a significant impact on visual function.
Posterior uveitis is considered one of the more sight-threatening forms of intraocular inflammation because of the critical role the retina and choroid play in central and peripheral vision. The choroid provides the blood supply that nourishes the outer layers of the retina, and disruption to either structure can lead to lasting changes in visual acuity if not identified and managed in a timely manner.
According to the American Uveitis Society (2023), uveitis is the fifth leading cause of vision loss in the developed world. The National Eye Institute (2023) reports that uveitis accounts for 10 to 15 percent of all cases of total blindness in the United States. Intermediate and posterior forms of uveitis carry particular concern because they affect the deeper structures of the eye that are directly responsible for detailed and peripheral vision.
At Washington Eye Institute, with locations in Greenbelt, Rockville, and Cumberland, Maryland, the retina and inflammatory eye disease team works closely with patients to identify these conditions early and develop individualized treatment strategies designed to preserve visual function over the long term.
Who Is a Good Candidate for Evaluation
Individuals who notice new or worsening floaters, hazy or blurred vision, or subtle changes in their visual field should consider seeking evaluation for possible intermediate or posterior uveitis. Unlike anterior uveitis, which frequently causes pain, redness, and light sensitivity, inflammation in the middle or back of the eye may be painless in its early stages. This absence of obvious discomfort can sometimes delay diagnosis.
A thorough evaluation is particularly important for patients whose visual symptoms do not improve with standard corrective lenses or who experience fluctuating vision quality that seems unrelated to refractive changes.
Certain systemic diseases are strongly associated with intermediate and posterior uveitis. Patients who have been diagnosed with conditions such as sarcoidosis, multiple sclerosis, or Behcet's disease may benefit from regular screening examinations, even in the absence of eye symptoms. Early detection of subclinical inflammation can help prevent complications before they affect daily vision.
- Sarcoidosis, which can cause granulomatous inflammation throughout the body including the eyes
- Multiple sclerosis, which is associated with intermediate uveitis in a notable subset of patients
- Behcet's disease, which can cause severe retinal vasculitis and posterior segment inflammation
Several infectious organisms can cause or trigger posterior uveitis. Individuals with a history of toxoplasmosis, cytomegalovirus (CMV) infection, tuberculosis, or syphilis should alert their eye care providers to these past diagnoses. Infectious causes of uveitis require a fundamentally different treatment approach than autoimmune causes, making accurate identification of the underlying trigger essential for effective management.
Some patients are referred for uveitis evaluation after routine eye examinations reveal unexpected findings such as vitreous haze, retinal lesions, or macular swelling. In many cases of intermediate and posterior uveitis, the underlying cause remains idiopathic, meaning that no specific systemic disease or infection can be identified despite thorough testing. Even when a definitive cause is not found, treatment can still be highly effective in controlling inflammation and protecting vision.
How Diagnosis and Treatment Work
Diagnosing intermediate and posterior uveitis begins with a detailed clinical history and a dilated fundus examination, which allows your uveitis specialist to directly observe the vitreous, retina, choroid, and optic nerve for signs of active or past inflammation. This examination is the foundation upon which all further testing is built.
Advanced imaging plays a central role in the diagnostic process. Optical coherence tomography (OCT) provides high-resolution cross-sectional images of the retina and can detect macular edema, a common complication of uveitis that may not be visible during standard examination. Fluorescein angiography involves injecting a special dye into the bloodstream and photographing the retinal blood vessels as the dye passes through them. This test reveals areas of vascular leakage, ischemia, and inflammation that help guide treatment decisions.
Because intermediate and posterior uveitis are frequently associated with systemic diseases and infections, your care team will typically order a targeted panel of blood work and imaging studies. These may include tests for inflammatory markers, infectious disease screening, and chest imaging to evaluate for conditions such as sarcoidosis or tuberculosis.
- Blood tests to screen for sarcoidosis, syphilis, tuberculosis, and other systemic conditions
- Chest X-ray or CT scan to look for hilar lymphadenopathy or pulmonary findings associated with sarcoidosis
- Additional specialized testing based on clinical presentation and patient history
- Collaboration with rheumatology, infectious disease, or pulmonology specialists when systemic conditions are identified
Once the type and cause of uveitis have been characterized, your provider will develop an individualized treatment plan. The primary goals of treatment are to control active inflammation, prevent structural damage to the eye, and minimize side effects from medications. The specific approach depends on whether the inflammation is autoimmune, infectious, or idiopathic in origin, as the treatment strategies for these categories differ significantly.
For infectious uveitis, treatment focuses on addressing the underlying organism with appropriate antimicrobial therapy before or alongside anti-inflammatory measures. For autoimmune or idiopathic uveitis, the emphasis is on suppressing the immune response that is driving the inflammation.
Types of Treatment Options
Oral corticosteroids are frequently used as a first-line therapy for moderate to severe intermediate and posterior uveitis. These medications are effective at rapidly reducing inflammation and can provide significant symptom relief within days to weeks. However, because long-term use of systemic corticosteroids carries risks including elevated blood sugar, bone density loss, weight gain, and increased susceptibility to infection, they are generally used as a bridge therapy while longer-term steroid-sparing treatments are initiated.
Your care team will carefully monitor your response to corticosteroid therapy and work to taper the dose as quickly as it is safe to do so. The goal is to achieve and maintain control of inflammation at the lowest effective dose, or to transition to alternative immunosuppressive agents that can serve as long-term maintenance therapy.
For patients who require ongoing treatment to prevent recurrent inflammation, steroid-sparing immunosuppressive medications offer an important alternative to long-term corticosteroid use. These medications work by modulating the immune system to reduce the inflammatory response without the cumulative side effects associated with prolonged steroid therapy.
- Conventional immunosuppressive agents that have been used effectively in uveitis management for many years
- Biologic therapies that target specific components of the immune response involved in ocular inflammation
- Combination approaches that may use multiple agents together for more effective inflammation control
Transitioning to steroid-sparing therapy requires careful monitoring through regular blood tests and clinical examinations. Your uveitis specialist will work with you to find the medication regimen that provides the best balance of inflammation control and tolerability for your individual situation.
Intravitreal injections deliver medication directly into the vitreous cavity of the eye, allowing high concentrations of anti-inflammatory agents to reach the site of inflammation while minimizing systemic exposure. This approach is particularly valuable for managing macular edema associated with uveitis and for treating inflammation that is limited to one eye.
Local steroid implants, which are placed inside the eye during a brief office procedure, can provide sustained release of anti-inflammatory medication over weeks to months. These implants reduce the need for frequent injections and can be especially helpful for patients who have difficulty tolerating systemic medications. Your provider will discuss the benefits and considerations of local versus systemic therapy based on your specific pattern of inflammation.
When posterior uveitis is caused by an infectious organism, directed antimicrobial therapy is essential. Toxoplasmosis, one of the most common infectious causes of posterior uveitis, requires a specific combination of antiparasitic and antibiotic medications. CMV retinitis is treated with antiviral agents. Tuberculosis-related uveitis necessitates a full course of anti-tuberculosis therapy, typically coordinated with an infectious disease specialist.
Treating the underlying infection is the cornerstone of management in these cases. Anti-inflammatory therapy may be used alongside antimicrobial treatment to limit damage from the inflammatory response, but suppressing inflammation without addressing the infection can lead to worsening of the condition.
What to Expect During Your Care
Your first visit to Washington Eye Institute for a uveitis evaluation will typically be longer than a routine eye appointment. Expect a comprehensive examination that includes dilation of both pupils, detailed imaging of the retina and vitreous, and a thorough discussion of your medical history and symptoms. If laboratory testing or additional imaging is needed, your care team will guide you through the process and explain what each test is designed to evaluate.
It is helpful to bring a list of all current medications, any relevant medical records from other specialists, and a written summary of your eye symptoms including when they started and how they have changed over time. This information helps your uveitis specialist build the most complete picture of your condition.
Once treatment begins, you will likely have follow-up appointments at regular intervals to monitor your response. These visits typically include a dilated eye examination and may include repeat OCT imaging to track changes in macular edema or other structural findings. Your provider will assess whether the inflammation is improving, stable, or worsening, and adjust your treatment plan accordingly.
- Follow-up examinations may be scheduled every few weeks during active inflammation
- Blood tests may be required periodically to monitor for medication side effects
- Imaging studies will be repeated as needed to evaluate treatment response
- Communication with other specialists involved in your care will occur as needed
Intermediate and posterior uveitis can lead to several complications that your care team will monitor for throughout the course of your treatment. Cystoid macular edema, which is swelling in the central part of the retina, is one of the most common causes of vision loss in uveitis patients. Cataracts can develop as a result of the inflammation itself or as a side effect of corticosteroid treatment. Retinal detachment, though less common, can occur in eyes with chronic inflammation or vitreous traction.
Optic nerve damage is another potential complication that may result from chronic inflammation, elevated eye pressure, or both. Your provider will check your intraocular pressure regularly and evaluate the health of the optic nerve at each visit. Early detection of complications allows for timely intervention that can help preserve visual function.
Many forms of intermediate and posterior uveitis follow a chronic or recurrent pattern, which means that ongoing monitoring remains important even during periods when the inflammation appears quiet. Tapering or discontinuing medications too quickly can lead to flare-ups that may cause additional damage to ocular structures. Your uveitis specialist will work with you to develop a long-term monitoring schedule tailored to your specific condition and treatment history.
Your Journey at Washington Eye Institute
Managing intermediate and posterior uveitis often requires coordination among multiple medical disciplines. At Washington Eye Institute, the retina and inflammatory eye disease team collaborates with rheumatologists, pulmonologists, infectious disease specialists, and other providers to ensure that both the ocular and systemic components of your condition are addressed comprehensively. This multidisciplinary approach is particularly important for patients whose uveitis is associated with systemic autoimmune or infectious diseases.
Your care team will serve as the central point of coordination for your eye-related care, communicating with your other physicians to align treatment strategies and avoid potential medication interactions. This collaborative model helps ensure that decisions made by one specialist take into account the full scope of your health needs.
Washington Eye Institute offers uveitis evaluation and treatment at our Greenbelt, Rockville, and Cumberland locations throughout Maryland. Having multiple locations allows patients to receive specialized inflammatory eye disease care closer to home, reducing the burden of frequent follow-up visits that are often necessary for managing these conditions. Each location is equipped with the advanced imaging technology needed to accurately diagnose and monitor uveitis.
Every patient's experience with uveitis is different, and your care team recognizes that treatment plans must reflect your individual circumstances, values, and goals. Whether your uveitis is newly diagnosed or has been managed for years, your provider will take the time to explain your condition, discuss all available treatment options, and involve you in decisions about your care. Education is an ongoing part of the process, because patients who understand their condition are better equipped to recognize early signs of recurrence and seek timely evaluation.
The overarching goal of uveitis management at Washington Eye Institute is to preserve your vision and quality of life over the long term. This means not only treating active inflammation but also proactively managing complications, minimizing medication side effects, and maintaining a monitoring schedule that catches potential problems early. Your care team is committed to supporting you through every stage of your treatment journey, from initial diagnosis through long-term maintenance and beyond.
Questions and Answers
Intermediate uveitis primarily affects the vitreous and the pars plana, which are located in the middle portion of the eye. Posterior uveitis involves inflammation of the choroid, the retina, or both, which are located at the back of the eye. Some patients may have inflammation that overlaps both regions, which is referred to as panuveitis. The distinction matters because the location of inflammation influences the symptoms a patient experiences, the potential complications, and the approach to treatment.
If left untreated or inadequately managed, both intermediate and posterior uveitis can lead to complications that affect vision. Macular edema, cataract formation, retinal detachment, and optic nerve damage are among the complications that can impact visual acuity. However, with timely diagnosis and appropriate treatment, many patients are able to maintain good functional vision. The key is early detection and consistent follow-up care to control inflammation and address complications as they arise.
Intermediate and posterior uveitis are frequently associated with systemic diseases such as sarcoidosis, tuberculosis, and autoimmune conditions. Blood tests and imaging studies help your care team determine whether an underlying cause is present, which directly influences treatment decisions. For example, uveitis caused by an infection requires antimicrobial therapy, while autoimmune-related uveitis is managed with immunosuppressive medications. Identifying the underlying cause leads to more targeted and effective treatment.
The duration of treatment varies considerably depending on the type and cause of uveitis, the severity of inflammation, and how your eyes respond to therapy. Some patients with a single episode of infectious uveitis may complete a defined course of treatment and not require ongoing medication. Patients with chronic autoimmune or idiopathic uveitis may need steroid-sparing immunosuppressive therapy for an extended period. Your uveitis specialist will regularly reassess your condition and discuss the appropriate timing for any changes to your treatment plan.
Most patients report that intravitreal injections are far more comfortable than they anticipated. Before the injection, your provider will apply topical numbing drops and an antiseptic solution to the eye. While you may feel brief pressure during the procedure, significant pain is uncommon. The injection itself takes only a few seconds, and most patients are able to return to normal activities the same day. Your care team will provide detailed instructions about what to expect before, during, and after the procedure.
If you notice a sudden increase in floaters, new blurriness, flashing lights, a shadow or curtain in your peripheral vision, or any other significant change in your eyesight between scheduled visits, you should contact Washington Eye Institute promptly. Recurrent inflammation can sometimes be detected and managed more effectively when addressed early. Your care team can advise you on whether an earlier appointment is warranted based on the symptoms you describe. Keeping a record of any visual changes can also be helpful for your provider during follow-up evaluations.